What Happened? Shares of wellness company Medifast (NYSE:MED) jumped 37.5% in the afternoon session after the company reported second-quarter results that su...
Medifast (NYSE:MED) reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or
Wellness company Medifast (NYSE:MED) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 27.6% year on year to $76.38 mil...
Gainers Medifast (NYSE:MED) stock increased by 10.7% to $10.78 during Monday's after-market session. The market value of their outstanding shares is at $108.0 million. The company's, Q2 earnings came out today.
Wellness company Medifast (NYSE:MED) will be reporting results this Monday after market hours. Here’s what you need to know. Medifast beat analysts’ revenue ...
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Since January 2026, Medifast has been in a holding pattern, posting a small return of 3.3% while floating around $11.05. Is now the time to buy Medifast, or ...
Wellness company Medifast (NYSE:MED) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 34.3% year on year to $76.04 m...
Wellness company Medifast (NYSE:MED) will be reporting earnings this Monday afternoon. Here’s what to expect. Medifast beat analysts’ revenue expectations la...
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding...
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the personal care industry, including Coty (NYSE:COTY) and its pe...
Consumer staples stocks are solid insurance policies in frothy markets ripe for corrections. Surprisingly, the sector hasn’t played its shielding role over t...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
What a brutal six months it’s been for Medifast. The stock has dropped 27.7% and now trades at $9.88, rattling many shareholders. This was partly driven by i...
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the personal care stocks, including Medifast (NYSE:MED) and its peers. While personal c...
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whet...
Medifast’s fourth quarter results outperformed Wall Street’s revenue expectations, which the market responded to positively. Management attributed this to early signs of success from its transition to a metabolic health-focused business model and improvements in coach productivity. CEO Dan Chard highlighted that this was the first quarter since mid-2022 where coach productivity turned positive year-over-year, up 6%. Chard noted, “These early performance metrics are yet to have appreciable impact on our revenue, but they are nonetheless early signs of the improving performance of our coaches.”
